How MRI and Genetics Predict Uterine Fibroid Trajectory
Uterine fibroids remain the most common benign pelvic neoplasms in women. However, clinicians now recognize that distinct uterine leiomyoma subtypes drive variable surgical trajectories and drug responses. A landmark retrospective investigation evaluated 720 genotyped tumors. Consequently, the study linked specific molecular drivers to clinical behaviors and magnetic resonance imaging (MRI) features.
Genomic Landscape of Uterine Leiomyoma Subtypes
Researchers classified tumors into four primary genomic categories. These categories included MED12-mutant, HMGA2-overexpressing, FH-deficient, and triple-negative variants. Notably, each genotype exhibited unique anatomical and clinical patterns. HMGA2-driven tumors frequently presented as solitary, submucosal masses. In contrast, FH-deficient tumors showed the highest rate of multiplicity. Therefore, molecular classification explains the marked clinical heterogeneity seen in routine practice.
Pharmacogenomic Responses to Hormonal Therapy
Preoperative gonadotropin-releasing hormone agonists (GnRHa) frequently reduce fibroid burden. However, pharmacogenomic responses differ significantly across genotypes. The study evaluated 84 patients receiving preoperative GnRHa. Notably, MED12-mutant tumors exhibited significantly lower volume reduction than triple-negative variants. Therefore, clinicians must recognize that MED12 status indicates relative resistance to hormonal shrinkage.
Surgical Recurrence and Re-Intervention Risks
Long-term surgical outcomes also depended on molecular classification. Among 502 myomectomy patients followed for over 12 months, FH-deficient tumors carried the highest risk of re-intervention. Furthermore, this aggressive recurrence pattern remained prominent even without postoperative GnRHa. Consequently, surgeons must monitor patients with FH-deficient lesions closely for early recurrent growth.
MRI-Based Triage and Preoperative Imaging Markers
Magnetic resonance imaging provides valuable non-invasive clues before surgery. Specifically, low T2-weighted signal intensity correlates strongly with MED12 mutations. In contrast, a mixed high T2 signal reliably flags FH deficiency. Moreover, this mixed high signal predicts elevated surgical re-intervention rates. Thus, T2-weighted MRI facilitates phenotype-genotype triage to optimize personalized surgical planning.
Frequently Asked Questions
Q1: Why do MED12-mutant fibroids show poor response to GnRH agonists?
MED12 mutations alter cellular signaling pathways that govern extracellular matrix accumulation and proliferation. Consequently, these tumors demonstrate reduced volumetric shrinkage during preoperative hormonal down-regulation.
Q2: What is the clinical significance of detecting FH-deficient leiomyomas?
FH-deficient fibroids carry a higher rate of tumor multiplicity and long-term surgical recurrence. In addition, FH deficiency may indicate hereditary leiomyomatosis and renal cell cancer syndrome.
Q3: How does T2-weighted MRI help triage uterine leiomyoma subtypes?
Low T2 signal intensity specifically identifies MED12 mutations, whereas a mixed hyperintense T2 signal predicts FH-deficient tumors and higher recurrence risks.
References
- Liu X et al. Clinical Trajectories and MRI-Based Triage of Uterine Leiomyoma Molecular Subtypes: A Large-Scale Retrospective Analysis of 720 Genotyped Tumors. Am J Obstet Gynecol. 2026 Sep 03. doi: undefined. PMID: 42692323.
- Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mod Pathol. 2017;30(10):1497-1506.
- Roller LA, Khorashadi L, Jagannathan JP, et al. MRI, clinical, and radiomic models for differentiation of uterine leiomyosarcoma and leiomyoma. Abdom Radiol. 2024;49(7):2284-2296.
